Teva Pharmaceutical Industries has agreed to pay US$1.1 million to settle antitrust claims by buyers of Shire’s ADHD drug Intuniv, who accused Shire and Teva’s predecessor Actavis of delaying the launch of a generic version of the drug through an illegal settlement.
In a motion filed Monday, May 24, in federal court in Boston, the plaintiffs asked US District Judge Allison Burroughs to approve the deal, saying it would provide “substantial relief” to a class of consumers, known as indirect purchasers because they bought Intuniv through intermediaries. Teva first disclosed the settlement in December, but did not reveal its terms.
The company previously reached a US$20 million settlement with a class of direct purchasers, like drug wholesalers and distributors, which has already received preliminary approval. If Burroughs grants both settlement final approval, Teva will exit the litigation.
“We are pleased to move this forward on behalf of the proposed class,” said plaintiffs’ lawyer Conlee Whiteley of Kanner & Whiteley.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
